Stephen B. Shrewsbury, MD

Chief Medical Officer
Impel Pharmaceuticals
Seattle, Washington

Presentation(s):

• Poster Number-3 - Early Prediction of Response to INP104 for the Acute Treatment of Migraine

  Poster Abstracts

• Poster Number-1 - Exploratory Efficacy of INP104 in Migraine Patients By Prior Treatment

  Poster Abstracts

• Poster Number-2 - Exploratory Efficacy of INP104 in Patients Using Concomitant Preventive Migraine Medications

  Poster Abstracts

• Poster Number-4 - Improvements in Productivity and Disability With INP104 as Assessed by the Migraine Disability Assessment Scale (MIDAS): Results From the Phase 3 STOP 301 Study

  Poster Abstracts